Menu

Blog

Archive for the ‘biotech/medical’ category: Page 304

Sep 2, 2023

Can Epigenetic Reprogramming Rejuvenate Cells & Extend Lifespan?

Posted by in categories: biotech/medical, genetics, life extension

In this article, the fourth installment of our five-part series on different pathways of aging, we look at the rejuvenation of cells, tissues, and stem cells, a topic that has been gaining increasing popularity thanks to remarkable advancements in the field of epigenetic reprogramming. Recent research suggests that despite the accumulation of molecular damage over time, cells and tissues can indeed undergo rejuvenation. We’ll be exploring key subjects such as Epigenetic reprogramming, PGC1a and GSK3β, Telomerase (TERT), as well as Apoptosis and senescence. Join us on this enlightening journey as we uncover the groundbreaking discoveries that are shaping the future of aging research.

The idea for reprogramming was simple yet beautiful. Children are born young, even though their parents are old, because they have undergone a process of cellular reprogramming that leads to rejuvenation.

Sep 2, 2023

Stanford Medicine first to try out novel tumor-targeting radiation therapy machine

Posted by in category: biotech/medical

Radiation therapy is a key component of care for many types of cancers. But some tumors can be more difficult than others to treat. Cancers in the lungs, for example, move with each breath, while tumors that have metastasized to many places in the body can require repeated radiation sessions.

Earlier this week, Stanford Medicine launched a new method of delivering radiation that uses signals from cancer-targeting molecules called tracers to target tumors in real time. It is the first time the new approach, known as biology-guided radiation therapy or SCINTIXTM, has been used in a clinic.

Continue reading “Stanford Medicine first to try out novel tumor-targeting radiation therapy machine” »

Sep 2, 2023

A Gene Behind a Key Senescence Biomarker

Posted by in category: biotech/medical

A paper published in GeroScience has described a gene responsible for a key biomarker of cellular senescence.

However, SA-ß-gal’s actual relationship to senescence processes has not been fully explored. In order to explore its potential as a biomarker, these researchers developed an RNA-binding protein that restricts SA-ß-gal expression both in C.elegans worms and in human cell cultures, and their experiments provided some insights into how this compound works.

Sep 2, 2023

The Cure to AI Fatigue: Striking a Balance Between Humans and Artificial Intelligence

Posted by in categories: biotech/medical, information science, robotics/AI

Artificial Intelligence has transformed how we live, work, and interact with technology. From voice assistants and chatbots to recommendation algorithms and self-driving cars, AI has suddenly become an integral part of our daily lives, just a few months after the release of ChatGPT, which kickstarted this revolution.

However, with the increasing prevalence of AI, a new phenomenon called “AI fatigue” has emerged. This fatigue stems from the overwhelming presence of AI in various aspects of our lives, raising concerns about privacy, autonomy, and even the displacement of human workers.

AI fatigue refers to the weariness, frustration, or anxiety experienced by individuals due to the overreliance on AI technologies. While AI offers numerous benefits, such as increased efficiency, improved decision-making, and enhanced user experiences, it also presents certain drawbacks. Excessive dependence on AI can lead to a loss of human agency, diminishing trust in technology, and a feeling of disconnection from the decision-making process.

Sep 2, 2023

What is The Field of Diverse Intelligence? Hacking the Spectrum of Mind & Matter | Michael Levin

Posted by in categories: bioengineering, biotech/medical, computing, information science, mathematics

Michael Levin is a Distinguished Professor in the Biology department at Tufts University. He holds the Vannevar Bush endowed Chair and serves as director of the Allen Discovery Center at Tufts and the Tufts Center for Regenerative and Developmental Biology. To explore the algorithms by which the biological world implemented complex adaptive behavior, he got dual B.S. degrees, in CS and in Biology and then received a PhD from Harvard University. He did post-doctoral training at Harvard Medical School, where he began to uncover a new bioelectric language by which cells coordinate their activity during embryogenesis. The Levin Lab works at the intersection of developmental biology, artificial life, bioengineering, synthetic morphology, and cognitive science.

✅EPISODE LINKS:
👉Round 1: https://youtu.be/v6gp-ORTBlU
👉Mike’s Website: https://drmichaellevin.org/
👉New Website: https://thoughtforms.life.
👉Mike’s Twitter: https://twitter.com/drmichaellevin.
👉Mike’s YouTube: https://youtube.com/@drmichaellevin.
👉Mike’s Publications: https://tinyurl.com/yc388vvk.
👉The Well: https://www.youtube.com/watch?v=0a3xg4M9Oa8 & https://youtu.be/XHMyKOpiYjk.
👉Aeon Essays: https://aeon.co/users/michael-levin.

Continue reading “What is The Field of Diverse Intelligence? Hacking the Spectrum of Mind & Matter | Michael Levin” »

Sep 2, 2023

Michael Levin: “Non-neural, developmental bioelectricity as a precursor for cognition”

Posted by in categories: biotech/medical, evolution, neuroscience

Plenary Talk by Michael Levin on “Non-neural, developmental bioelectricity as a precursor for cognition: Evolution, synthetic organisms, and biomedicine” at the Virtual Miniature Brain Machinery Retreat, September 16, 2021. Introduction by William Baker.

Michael Levin.
Director of the Allen Discovery Center.
Tufts University.

Continue reading “Michael Levin: ‘Non-neural, developmental bioelectricity as a precursor for cognition’” »

Sep 2, 2023

-Electricity of Life💡: Wonders of Bioelectricity and Regenerative Biology Prof Michael Levin

Posted by in categories: bioengineering, biotech/medical, life extension

Welcome to another exciting episode of our podcast series, where we dive deep into the world of science and innovation! In today’s episode, we have the privilege of interviewing Prof. Michael Levin, a renowned researcher in the fields of bioelectricity, regenerative biology, and biophysics.

Prof. Levin is the director of the Allen Discovery Center at Tufts University and has been making groundbreaking discoveries that are revolutionizing the field of regenerative medicine. His research focuses on understanding the electrical communication within and between cells, and how this communication can be harnessed for tissue repair and regeneration.

Continue reading “-Electricity of Life💡: Wonders of Bioelectricity and Regenerative Biology Prof Michael Levin” »

Sep 2, 2023

Restoring A Person’s Voice Using A Brain-Computer Interface

Posted by in categories: biotech/medical, computing, neuroscience

Being able to vocalize is one of the most essential elements of the human experience, with infants expected to start babbling their first words before they’re one year old, and much of their further life revolving around interacting with others using vocalizations involving varying degrees of vocabulary and fluency. This makes the impairment or loss of this ability difficult to devastating, as is the case with locked-in syndrome (LIS), amyotrophic lateral sclerosis (ALS) and similar conditions, where talking and vocalizing has or will become impossible.

In a number of concurrent studies, the use of a brain-computer interface (BCI) is investigated to help patients suffering from LIS (Sean L. Metzger et al., 2023) and ALS (Francis R. Willett et al., 2023) to regain their speaking voice. Using the surgically implanted microelectrode arrays (Utah arrays) electrical impulses pertaining to the patient’s muscles involved in speaking are recorded and mapped to phonemes, which are the elements that make up speech. Each of these phonemes requires a specific configuration of the muscles of the vocal tract (e.g. lips, tongue, jaw and larynx), which can be measured with a fair degree of accuracy.

In the case of the study by Sean L. Metzger et al. as recently published in Nature, the accompanying research article on the University of California San Francisco website details the story of their patient: Ann. At the age of 30, Ann suffered a brainstem stroke which rendered her essentially fully paralyzed. As an LIS patient she lacked for a long time even the ability to move her facial muscles.

Sep 2, 2023

Innovative insights into effects of hematopoietic changes on colon cancer, unveiling therapeutic avenues

Posted by in categories: biotech/medical, genetics

In a recent study published in the Journal of Experimental Medicine, researchers investigated whether bone marrow-derived cells with heterozygous loss of Dnmt3a (Dnmt3a+/Δ), the most common genetic alteration in clonal hematopoiesis (CH), contribute to colitis-associated colon cancer (CAC) pathogenesis.

Study: Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer. Image Credit: vetpathologist/Shutterstock.com.

Sep 2, 2023

Promising New Cancer Drug May Kill Cancer Cells with Minimal Side Effects

Posted by in categories: biotech/medical, chemistry

An exciting new cancer drug has recently entered into a phase 1 clinical trial supported by promising pre-clinical work. The drug, named AOH1996, targets a protein called proliferating cell nuclear antigen (PCNA), an essential player in the biological processes of DNA replication and repair. A team of researchers from City of Hope published the data describing how they identified and characterized AOH1996 in Cell Chemical Biology last week. Since then, the news of AOH1996 has appeared prominently in both scientific and mainstream media.

Using a rational drug design approach that develops drugs based on their specific biological targets, the researchers identified AOH1996. Lead researcher Linda Malkas named the drug after Anna Oliva Healey, a girl born in 1996 who succumbed to neuroblastoma at age 9.

In the laboratory, the researchers tested AOH1996 on over 70 different kinds of tumor cells as well as some healthy control cells. While the drug killed the cancer cells, it notably does not affect non-cancer cells, including blood cells and the cells lining the airway. This indicates AOH1996 as a selective drug that will suppress tumor growth but likely not cause adverse effects that can occur when a cancer drug damages healthy cells.

Page 304 of 2,560First301302303304305306307308Last